PAMS
ADMA icon

Pictet Asset Management (Switzerland)’s ADMA Biologics ADMA Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$54.2K Sell
14,696
-17,778
-55% -$65.9K ﹤0.01% 1929
2023
Q1 		$107K Buy
32,474
+10,295
+46% +$35.6K ﹤0.01% 1861
2022
Q4 		$86K Buy
+22,179
New +$68.4K ﹤0.01% 1894

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s ADMA Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) reduced its ADMA Biologics (ADMA) stake by 55% in Q2 2023, selling an estimated $65.9K and leaving 14,696 shares worth $54.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1929.

Pictet Asset Management (Switzerland) first reported a position in ADMA in Q4 2022 and has held it in 3 quarters since. The position peaked at $107K in Q1 2023. 179 funds tracked by Wall St. Rank hold ADMA as of Q2 2023.

  • Pictet Asset Management (Switzerland) held 14,696 shares of ADMA Biologics worth $54.2K as of Q2 2023.
  • Pictet Asset Management (Switzerland) sold 17,778 ADMA Biologics shares in Q2 2023, an estimated $65.9K.
  • ADMA Biologics made up ﹤0.01% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #1929 holding.
  • Pictet Asset Management (Switzerland) first reported a position in ADMA Biologics in Q4 2022 and has held it in 3 quarters since.
  • Pictet Asset Management (Switzerland)'s ADMA Biologics position peaked at $107K in Q1 2023.
  • 179 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.